Human Clinical Trials
Exoxemis has completed a placebo controlled, randomized, international, Pivotal, Phase III, human clinical trial with 250 human subjects in each arm, at 25 U.S. and 5 Israeli sites. This study provides direct evidence that Zempia® is safe for use in open wounds—it does not interfere with normal wound healing.
Action of Zempia®
Has broad microbicidal activity against all wound pathogens; kills antibiotic resistant bacteria; is effective in killing gram-negative and gram-positive bacteria, viruses, spores, yeast and fungi.
E-101 Solution (Zempia®) Demonstrates Viricidal
Properties Against Coronavirus in Mucin.
ePoster with audio and slide presentation from the
The ESCMID Conference on Coronavirus Disease (ECCVID)
For Immediate Release
Groundbreaking Research Points Towards Zempia®
As a Proposed New Weapon in Medicine’s Armamentarium to Fight Sepsis
Myeloperoxidase and Eosinophil Peroxidase Conclusively
Shown to Inactivate Endotoxin and Lipid A.
Jackson T. “Steve” Stephens
Founder & CEO
PARTNER WITH EXOXEMIS
Today, Exoxemis, Inc. is well qualified to partner with a medical device or pharmaceutical company to conduct further testing, obtain regulatory approval and to more quickly optimize Zempia® market share. An exclusive licensing agreement is available for Zempia® for several applications in a number of potential markets: for use in conjunction with large joint implants; urinary catheters; dental implants and oral surgeries; for use in the ER, in wound treatments, colorectal, HEENT, Plastics/Burn. . . .really in any surgery or condition involving an open wound that is susceptible to infection. This includes skin care, dermatology, even cosmetics. We believe that Zempia® could be an effective weapon to fight AMR and HAI’s infections that are now a crisis and plaguing our hospital systems.